Chimeric 4/9ICR reprograms immunosuppressive IL-4 signals to enhance B7-H3-targeted CAR-T cell efficacy against triple-negative breast cancer.
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.